Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

722
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
722
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

2.4K
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
2.4K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

1.8K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.8K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

786
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
786
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

538
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
538

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Securing the Future for a Major Academic Cardiovascular Program: Hardwiring a Referral Network and Preparing for a Transition to Value-Based Reimbursement.

Hospital topics·2020
Same author

Managing Cardiovascular Risk Factors without Medications: What is the Evidence?

Cardiovascular & hematological agents in medicinal chemistry·2020
Same author

Inflammation May be the Future of Cardiovascular Risk Reduction: Does Colchicine have a Current Indication?

American journal of cardiovascular drugs : drugs, devices, and other interventions·2020
Same author

Alcohol Excess Is an Insufficiently Considered Cause of Malignant Refractory Hypertension.

Angiology·2019
Same author

The Superior Mesenteric Artery: From Syndrome in the Young to Vascular Atherosclerosis in the Old.

Cardiovascular & hematological agents in medicinal chemistry·2019
Same author

Imaging Characteristics and Significance of Coronary Artery Mismatch Lesions.

Angiology·2019

Related Experiment Video

Updated: Mar 7, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K

Low-Density Lipoprotein Cholesterol (LDL-C): How Low?

Thomas F Whayne1

  • 1Wethington Building, 900 South Limestone Street, Lexington, KY 40536-0200. United States.

Current Vascular Pharmacology
|March 2, 2017
PubMed
Summary

Lowering low-density lipoprotein cholesterol (LDL-C) is crucial for cardiovascular health. Very low LDL-C levels, potentially as low as 20 mg/dL, may be safe and beneficial for high-risk patients with extensive atherosclerosis.

Keywords:
Coronary artery diseaselow-density lipoprotein cholesterolperipheral arterial diseaseproprotein convertase subtilisin/ kexin type 9statins

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
High-Density Lipoprotein-Specific Phospholipid Efflux Assay
07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

523

Related Experiment Videos

Last Updated: Mar 7, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
High-Density Lipoprotein-Specific Phospholipid Efflux Assay
07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

523

Area of Science:

  • Cardiology
  • Lipidology
  • Preventive Medicine

Background:

  • Low-density lipoprotein cholesterol (LDL-C) is a primary risk factor for cardiovascular disease.
  • Therapeutic lowering of LDL-C reduces atherosclerotic events.
  • Individualized LDL-C targets are essential, considering baseline levels and patient risk.

Purpose of the Study:

  • To investigate the safety and justification of very low LDL-C levels in high-risk cardiovascular patients.
  • To explore the clinical implications of achieving extremely low LDL-C through various means.
  • To provide context on the

Main Methods:

  • Literature review and synthesis of available clinical evidence.
  • Discussion of clinical scenarios associated with naturally very low LDL-C.
  • Contextualization of therapeutic strategies for LDL-C reduction.

Main Results:

  • Certain conditions (e.g., PCSK9 mutations, hypobetalipoproteinemia) are linked to very low LDL-C in healthy individuals.
  • A therapeutic target of LDL-C as low as 20 mg/dL may be justifiable in specific high-risk populations.
  • No definitive universal safe lower limit for LDL-C can be established.

Conclusions:

  • Very low LDL-C levels (around 20 mg/dL) can be considered in patients with extensive atherosclerosis requiring plaque stabilization and regression.
  • Clinical decisions on LDL-C targets should be individualized based on risk and potential benefits.
  • Further research may be needed to define precise safe thresholds for LDL-C.